Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines may confer greater protection

10/22/2021 | 03:32pm EST

Oct 22 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

COVID-19 vaccines not linked with pregnancy loss

Two studies in major medical journals add to evidence that COVID-19 vaccines are safe before and during pregnancy. One study, published in The New England Journal of Medicine on Wednesday https://www.nejm.org/doi/full/10.1056/NEJMc2114466, tracked nearly 18,500 pregnant women in Norway, including about 4,500 who had miscarriages. Researchers found no link between COVID-19 vaccines and risk of first-trimester miscarriage, regardless of whether the vaccines were from Moderna, Pfizer and BioNTech, or AstraZeneca. Overall, the women with miscarriages were 9% less likely to have been vaccinated, according to the researchers' calculations. In a separate study published on Thursday in The Lancet https://www.sciencedirect.com/science/article/pii/S0140673621022 820, researchers tracked 107 women who became pregnant while participating in trials of AstraZeneca's vaccine in the UK, Brazil and South Africa. Seventy-two of the women had received the vaccine while the others got a placebo. AstraZeneca's vaccine had no effect on the odds of safely carrying the pregnancy to term, the researchers reported. "It is important that pregnant women are vaccinated since they have a higher risk of hospitalizations and COVID-19-complications, and their infants are at higher risk of being born too early," the authors of the Norwegian study wrote. "Also, vaccination during pregnancy is likely to provide protection to the newborn infant against COVID-19 infection in the first months after birth."

Vaccine combinations with different technologies may be best

Healthcare workers in France who got a first shot of AstraZeneca's COVID-19 vaccine and then the Pfizer/BioNTech vaccine for their second shot showed stronger immune responses than those who had received two shots of the Pfizer vaccine, in a recent study. Combining different technologies is known to boost immune responses to other viruses, and the current study suggests it may be true for the coronavirus as well. Both vaccines in the study deliver instructions that teach cells in the body to make a piece of protein that resembles the spike on the coronavirus and that triggers an immune response. But they do it in very different ways. Both protocols provided "safe and efficient" protection, said Vincent Legros of Universite de Lyon in France, coauthor of a report published on Thursday in Nature https://www.nature.com/articles/s41586-021-04120-y. But combining the AstraZeneca shot with the Pfizer/BioNTech vaccine "conferred even better protection" than two doses of Pfizer's shot, including against the Delta variant, Legros said. The two technologies combined induced an antibody response of better quality, with more neutralizing antibodies that could block the virus, and more cells that have been "trained" by the vaccine to have increased defense potential, he said. Combination vaccination "is safe and may provide interesting options... for clinicians to prevent SARS-CoV-2 infection," Legros concluded.

Cognitive problems seen in middle-aged COVID-19 survivors

A "substantial proportion" of middle-aged COVID-19 survivors with no previous dementia had cognitive problems more than half a year after diagnosis, researchers have found. They looked at 740 people who ranged in age from 38 to 59. About half were white, and 63% were female. On tests of thinking skills, 20% had trouble converting short-term memories to long-term memories, 18% had trouble processing information rapidly, and 16% had trouble with skills needed for planning, focusing attention, remembering instructions, and juggling multiple tasks. The average time from diagnosis was 7.6 months. About one-in-four patients had been hospitalized, but most of them were not critically ill. "We can't exactly say that the cognitive issues were lasting because we can't determine when they began," said Dr. Jacqueline Becker of the Icahn School of Medicine at Mount Sinai in New York City, who co-led the study published on Friday in JAMA Network Open https://bit.ly/3jsuM41. "But we can say that our cohort had higher than anticipated frequency of cognitive impairment" given that they were relatively young and healthy, Becker said.

Data support use of Pfizer vaccine in children and teens

The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a trial of children ages 5 to 11, the U.S. drugmaker said on Friday in briefing documents submitted to the U.S. Food and Drug Administration but not formally published. The children were given two shots of a 10-microgram dose of the vaccine - a third of the strength given to people 12 and older. The study was not primarily designed to measure efficacy against the virus. Instead, it compared the amount of neutralizing antibodies induced by the vaccine in the children to the response of recipients in their adult trial. Pfizer and BioNTech said the vaccine induced a robust immune response in the children. Outside advisers to the FDA are scheduled to meet on Tuesday to vote on whether to recommend authorization of the vaccine for that age group. A separate study from Israel conducted while the Delta variant was prevalent and published on Wednesday in The New England Journal of Medicine https://www.nejm.org/doi/full/10.1056/NEJMc2114290, compared nearly 95,000 12- to -18-year-olds who had received Pfizer's vaccine with an equal number of adolescents who had not been vaccinated. The results show the vaccine "was highly effective in the first few weeks after vaccination against both documented infection and symptomatic COVID-19 with the Delta variant" in this age group, the research team reported.

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

(Reporting by Nancy Lapid; Additional reporting by Michael Erman; Editing by Bill Berkrot)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.49% 8191 Delayed Quote.11.84%
MODERNA, INC. 1.73% 306.72 Delayed Quote.193.60%
All news about MODERNA, INC.
12/04U.S. administers 468.5 mln doses of COVID-19 vaccines- CDC
RE
12/04U.S. CDC Says Delivered 581,107,805 Doses Of Covid-19 Vaccine As Of Dec 4
RE
12/04Covid-19 - Nigeria Approves Booster Doses for Enhanced Protection
AQ
12/04Federal Contractor And Subcontractor Vaccine Mandate Temporarily Enjoined In Kentucky, ..
AQ
12/03U.S. administers 466.3 mln doses of COVID-19 vaccines - CDC
RE
12/03U.S. CDC Says Delivered 580,893,145 Doses Of Covid-19 Vaccine As Of Dec 3
RE
12/03U.S. CDC Reports Total Novel Coronavirus Cases Of 48,767,329 As Of Yesterday
RE
12/03Vaccine makers could make Omicron-specific booster, says Fauci
RE
12/03PUMP / DUMP #13 : This week's gainers and losers
12/03UK jabs deal to 'future-proof' immunisation
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 449 M - -
Net income 2021 11 169 M - -
Net cash 2021 12 344 M - -
P/E ratio 2021 11,7x
Yield 2021 -
Capitalization 124 B 124 B -
EV / Sales 2021 6,42x
EV / Sales 2022 4,93x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 306,72 $
Average target price 272,53 $
Spread / Average Target -11,1%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298
ICON PUBLIC LIMITED COMPANY39.92%22 206